MAX-4 is under clinical development by Maxinovel Pharmaceuticals and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MAX-4’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MAX-4 is under development for the treatment of myelodysplastic syndrome, acute myelocytic leukemia, metastatic colorectal cancer, relapsed/refractory acute myeloid leukemia, solid tumors, gastric cancer, small-cell lung cancer and adenocarcinoma of the gastroesophageal junction. The drug candidate is formulated as a capsule and administered through the oral route. It acts by targeting FMS like tyrosine kinase 3 (FLT3) and fibroblast growth factor receptor (FGFR).
Maxinovel Pharmaceuticals overview
Maxinovel Pharmaceuticals is a biotechnology company that specializes in disease areas characterized by high mortality and high morbidity with no effective treatment. The company is headquartered in China.
For a complete picture of MAX-4’s drug-specific PTSR and LoA scores, buy the report here.